Rates of febrile neutropenia and its causes in the real world

References

• Maldonado EB, Parsons S, Chen EY, Haslam A, Prasad V. Estimation of US patients with cancer who may respond to cytotoxic chemotherapy. Future Sci OA. 2020;6(8):FSO600. doi:10.2144/fsoa-2020-0024
   PubMed Web of Science ®Google Scholar
• Haslam A, Gill J, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs. JAMA Netw Open. 2020;3(3):e200423. doi:10.1001/jamanetworkopen.2020.0423
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–2266. doi:10.1002/cncr.21847
   PubMed Web of Science ®Google Scholar
• Shah C, Du X, Bishnoi R, Bian J. Risk of mortality in adult cancer febrile neutropenia patients with a machine learning approach. JCO. 2018;36(Suppl. 15):e13562–e13562. doi:10.1200/JCO.2018.36.15_suppl.e13562
   Web of Science ®Google Scholar
• Chirivella I, Bermejo B, Insa A, et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat. 2009;114(3):479–484. doi:10.1007/s10549-008-0018-1
   PubMed Web of Science ®Google Scholar
• Bosly A, Bron D, Van Hoof A, et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol. 2008;87(4):277–283. doi:10.1007/s00277-007-0399-y
   PubMed Web of Science ®Google Scholar
• Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol. 2014;90(3):190–199. doi:10.1016/j.critrevonc.2013.12.006
   PubMed Web of Science ®Google Scholar
• Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(Suppl. 5):v111–v118. doi:10.1093/annonc/mdw325
   PubMed Web of Science ®Google Scholar
• Becker PS, Griffiths EA, Alwan LM, et al. NCCN guidelines insights: hematopoietic growth factors, Version 1.2020. J Natl Compr Canc Netw. 2020;18(1):12–22. doi:10.6004/jnccn.2020.0002
   PubMed Web of Science ®Google Scholar
• Truong J, Lee EK, Trudeau ME, Chan KKW. Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis. Ann Oncol. 2016;27(4):608–618. doi:10.1093/annonc/mdv619
   PubMed Web of Science ®Google Scholar
• Dale DC, McCarter GC, Crawford J, Lyman GH. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw. 2003;1(3):440–454. doi:10.6004/jnccn.2003.0038
   Google Scholar
• Péron J, Maillet D, Gan HK, Chen EX, You B. Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review. J Clin Oncol. 2013;31(31):3957–3963. doi:10.1200/JCO.2013.49.3981
   Web of Science ®Google Scholar
• Lyman GH, Poniewierski MS, Culakova E. Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma. Expert Opin Drug Saf. 2016;15(4):483–492. doi:10.1517/14740338.2016.1146675
   PubMed Web of Science ®Google Scholar
• Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100(2):228–237. doi:10.1002/cncr.11882
   PubMed Web of Science ®Google Scholar
• Chao C, Page JH, Yang S-J, Rodriguez R, Huynh J, Chia VM. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. Ann Oncol. 2014;25(9):1821–1829. doi:10.1093/annonc/mdu203
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158–3167. doi:10.1200/JCO.2006.08.8823
   PubMed Web of Science ®Google Scholar
• Baig H, Somlo B, Eisen M, Stryker S, Bensink M, Morrow PK. Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level. J Oncol Pharm Pract. 2019;25(7):1576–1585. doi:10.1177/1078155218799859
   PubMed Web of Science ®Google Scholar
• Wang C-Y, Heldermon CD, Vouri SM, et al. Trends in use of granulocyte colony-stimulating factor following introduction of biosimilars among adults with cancer and commercial or Medicare insurance From 2014 to 2019. JAMA Netw Open. 2021;4(11):e2133474. doi:10.1001/jamanetworkopen.2021.33474
   Web of Science ®Google Scholar
• Weycker D, Li X, Tzivelekis S, et al. Burden of chemotherapy-induced febrile neutropenia hospitalizations in US Clinical Practice, by use and patterns of prophylaxis with colony-stimulating factor. Support Care Cancer 2017;25(2):439–447. doi:10.1007/s00520-016-3421-x
   PubMed Web of Science ®Google Scholar
• Zullo AR, Lou U, Cabral SE, Huynh J, Berard-Collins CM. Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia. J Oncol Pharm Pract. 2019;25(6):1357–1365. doi:10.1177/1078155218792698
   PubMed Web of Science ®Google Scholar
• Aapro M, Ludwig H, Bokemeyer C, et al. Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study). Ann Oncol. 2016;27(11):2039–2045. doi:10.1093/annonc/mdw309
   PubMed Web of Science ®Google Scholar
• Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Soft. 2010;36(3):1–48. doi:10.18637/jss.v036.i03
   Web of Science ®Google Scholar
• Del Mastro L, De Placido S, Bruzzi P, et al. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised Phase III trial. Lancet 2015;385(9980):1863–1872. doi:10.1016/S0140-6736(14)62048-1
   PubMed Web of Science ®Google Scholar
• Blohmer J-U, Schmid P, Hilfrich J, et al. Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised Phase III trial. Ann Oncol. 2010;21(7):1430–1435. doi:10.1093/annonc/mdp585
   Web of Science ®Google Scholar
• Socinski MA, Smit EF, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol. 2009;27(28):4787–4792. doi:10.1200/JCO.2009.23.1548
   PubMed Web of Science ®Google Scholar
• Quoix E, Breton JL, Daniel C, et al. Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: a Phase II study. Ann. Oncol. 2001;12(7):957–962. doi:10.1023/A:1011171722175
   Web of Science ®Google Scholar
• Hügli A, Moro D, Mermillod B, et al. Phase II trial of up-front accelerated thoracic radiotherapy combined with chemotherapy and optional up-front prophylactic cranial irradiation in limited small-cell lung cancer. Groupe d'Oncologie Thoracique des Régions Alpines. J Clin Oncol. 2000;18(8):1662–1667. doi:10.1200/JCO.2000.18.8.1662
   Web of Science ®Google Scholar
• Zatloukal P, Cardenal F, Szczesna A, et al. A multicenter international randomized Phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol. 2010;21(9):1810–1816. doi:10.1093/annonc/mdq036
   PubMed Web of Science ®Google Scholar
• Cardenal F, López-Cabrerizo MP, Antón A, et al. Randomized Phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999;17(1):12–18. doi:10.1200/JCO.1999.17.1.12
   PubMed Web of Science ®Google Scholar
• Szturz P, Wouters K, Kiyota N, et al. Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data. Oncologist. 2017;22(9):1056–1066. doi:10.1634/theoncologist.2017-0015
   PubMed Web of Science ®Google Scholar
• Noronha V, Joshi A, Patil VM, et al. Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a Phase III Randomized noninferiority trial. J Clin Oncol. 2018;36(11):1064–1072. doi:10.1200/JCO.2017.74.9457
   PubMed Web of Science ®Google Scholar
• Al-Batran S-E, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, Phase II/3 trial. Lancet. 2019;393(10184):1948–1957. doi:10.1016/S0140-6736(18)32557-1
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Wilson WH, Jung S-H, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the Phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790–1799. doi:10.1200/JCO.18.01994
   PubMed Web of Science ®Google Scholar
• Pignata S, Scambia G, Ferrandina G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized Phase III trial. J Clin Oncol. 2011;29(27):3628–3635. doi:10.1200/JCO.2010.33.8566
   PubMed Web of Science ®Google Scholar
• Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a Phase III, open-label, randomised controlled trial. Lancet. 2009;374(9698):1331–1338. doi:10.1016/S0140-6736(09)61157-0
   PubMed Web of Science ®Google Scholar
• Clamp AR, James EC, McNeish IA, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG Phase III randomised controlled trial. Lancet. 2019;394(10214):2084–2095. doi:10.1016/S0140-6736(19)32259-7
   PubMed Web of Science ®Google Scholar
• Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–237. doi:10.1200/JCO.2004.05.113
   PubMed Web of Science ®Google Scholar
• de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001;19(6):1629–1640. doi:10.1200/JCO.2001.19.6.1629
   PubMed Web of Science ®Google Scholar
• Culine S, Kramar A, Théodore C, et al. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol. 2008;26(3):421–427. doi:10.1200/JCO.2007.13.8461
   Web of Science ®Google Scholar
• Urban D, Urban GE, Margalit O, et al. Mortality among neutropenic cancer patients within the United States: the association with hospital volume. JCO Oncol Pract. 2021;17(4):e582–e592. doi:10.1200/OP.20.00115
   Google Scholar
• Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer. 2006;6(7):546–558. doi:10.1038/nrc1887
   PubMed Web of Science ®Google Scholar
• van Leeuwen RWF, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol. 2011;22(10):2334–2341. doi:10.1093/annonc/mdq761
   PubMed Web of Science ®Google Scholar
• Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99(8):592–600. doi:10.1093/jnci/djk130
   PubMedGoogle Scholar
• Buajordet I, Ebbesen J, Erikssen J, Brørs O, Hilberg T. Fatal adverse drug events: the paradox of drug treatment. J Intern Med. 2001;250(4):327–341. doi:10.1046/j.1365-2796.2001.00892.x
   PubMed Web of Science ®Google Scholar
• Miranda V, Fede A, Nobuo M, et al. Adverse drug reactions and drug interactions as causes of hospital admission in oncology. J Pain Symptom Manage. 2011;42(3):342–353. doi:10.1016/j.jpainsymman.2010.11.014
   PubMed Web of Science ®Google Scholar
• Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol. 2004;50(2):129–146. doi:10.1016/j.critrevonc.2004.01.001
   PubMed Web of Science ®Google Scholar
• Weycker D, Li X, Edelsberg J, et al. Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors. J Oncol Pract. 2015;11(1):47–54. doi:10.1200/JOP.2014.001492
   PubMed Web of Science ®Google Scholar